Natalie Hawryluk

Natalie Hawryluk is an accomplished expert in drug discovery and development with a solid academic background in chemistry. Currently serving as the Executive Director of Drug Discovery & Early Development at Edgewise Therapeutics and holding multiple advisory roles, including in the Expert Scientific Advisory Committee for Medicines for Malaria Venture and as a Scientific Advisor at Drugs for Neglected Diseases initiative. Previous experience includes leadership positions at Bristol-Myers Squibb, Celgene, Janssen, and Johnson & Johnson, where a focus was placed on global health programs addressing neglected diseases and various therapeutic areas. Educational credentials include a post-doctoral degree from Harvard University and a PhD from Brandeis University, both in organic chemistry, along with a BS from the University of Illinois Urbana-Champaign. Additionally, Natalie is the founder and president of LH Partners LLC, providing consultancy in medicinal chemistry and drug development.